Tissue Kinetics assay in rodents


Aim: To characterize the pharmacokinetics of test compound in a tissue and plasma after single dose administration to rodents.


Background information: Tissue distribution studies provide information on distribution and accumulation of a drug at the site of action. This information may be useful for understanding results from toxicological or pharmacological studies.

Tissue pharmacokinetics in rodents is conducted after single dose administration of the compound by the selected route and vehicle. At time points defined previously, blood samples and tissue are collected from each animal. After tissue homogenization and protein precipitation, compound is determined in brain and plasma by UPLC-MS/MS.


Compound requirement: dependent on species, dose and route

Turnaround time: 3 weeks 

Experimental design:

Dose and route: variable on request (e.g. oral, intraperitoneal)
Vehicle: variable depending on route
Samples: plasma and tissue at each time (8 sampling times up to 24 h)
Replicates: 2 animals / sampling time
Dilution factor of tissue homogenate: 5 (in saline phosphate buffer)
Analytical method: UPLC-MS/MS quantification in plasma and tissue after protein precipitation using calibration curves

Delivered results:

Plasma concentration-time curve
Tissue concentration-time curve
Standard pharmacokinetic parameters in plasma and tissue determined by non-compartmental analysis
Tissue-to-plasma exposure ratio
tissue kinetics3

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS